| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $719,958 ) |
| | 2024 | 2024 | THERANOSTEC INC | 5416 BRANINBURG CT | CARMICHAEL | CA | 95608-4702 | SACRAMENTO | USA | R44CA240068 | Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | 000 | 4 | NIH | 2/27/2024 | $719,958 |
| | 2024 | 2020 | THERANOSTEC INC | 5416 BRANINBURG CT | CARMICHAEL | CA | 95608-4702 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 3 | NIH | 6/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $849,788 ) |
| | 2023 | 2023 | THERANOSTEC INC | 5416 BRANINBURG CT | CARMICHAEL | CA | 95608-4702 | SACRAMENTO | USA | R44CA240068 | Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | 000 | 3 | NIH | 4/18/2023 | $849,788 |
| | 2023 | 2020 | THERANOSTEC INC | 5416 BRANINBURG CT | CARMICHAEL | CA | 95608-4702 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 3 | NIH | 9/19/2023 | $0 |
| | 2023 | 2019 | THERANOSTEC INC | 5416 BRANINBURG CT | CARMICHAEL | CA | 95608-4702 | SACRAMENTO | USA | R43CA240068 | Transformable nano-theranostics for image-guided interventions in head and neck squamous cell carcinoma | 000 | 1 | NIH | 3/10/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $399,999 ) |
| | 2022 | 2022 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R43CA272110 | Sub-100 nm and scalable self-therapeutic nanoparticles to target autophagy in pancreatic cancer | 000 | 1 | NIH | 9/8/2022 | $399,999 |
| | 2022 | 2021 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA240068 | Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | 000 | 2 | NIH | 8/31/2022 | $0 |
| | 2022 | 2020 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 3 | NIH | 8/1/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $480,254 ) |
| | 2021 | 2021 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA240068 | Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma | 000 | 2 | NIH | 8/10/2021 | $480,254 |
| | 2021 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R43HD097970 | Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor | 000 | 1 | NIH | 1/22/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,496,599 ) |
| | 2020 | 2020 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 001 | 3 | NIH | 8/14/2020 | $1,496,599 |
| | 2020 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 1 | NIH | 8/12/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $803,046 ) |
| | 2019 | 2019 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R43CA240068 | Transformable nano-theranostics for image-guided interventions in head and neck squamous cell carcinoma | 000 | 1 | NIH | 8/5/2019 | $300,000 |
| | 2019 | 2019 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 001 | 2 | NIH | 8/27/2019 | $503,046 |
| | 2019 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R43HD097970 | Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor | 000 | 1 | NIH | 3/20/2019 | $0 |
| | 2019 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 1 | NIH | 11/9/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $516,894 ) |
| | 2018 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R44CA228645 | Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers | 000 | 1 | NIH | 8/30/2018 | $291,894 |
| | 2018 | 2018 | THERANOSTEC INC | 9944 NESTLING CIR | ELK GROVE | CA | 95757-8217 | SACRAMENTO | USA | R43HD097970 | Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor | 000 | 1 | NIH | 9/26/2018 | $225,000 |
|
|
